OTH-12 Efficacy and safety of vedolizumab subcutaneous formulation for ulcerative colitis: results of the visible trial | Gut

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via BSG

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via BSG

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals More

Article metrics

Inflammatory Bowel Disease

Orals

OTH-12 Efficacy and safety of vedolizumab subcutaneous formulation for ulcerative colitis: results of the visible trial

Free

Online download statistics by month:

Online download statistics by month: June 2019 to March 2021

	Abstract	Full	Pdf
Jun 2019	67	0	17
Jul 2019	196	0	16
Aug 2019	136	0	23
Sep 2019	159	0	23
Oct 2019	255	0	33
Nov 2019	148	0	21
Dec 2019	131	0	9
Jan 2020	112	0	9
Feb 2020	144	0	7
Mar 2020	122	0	13
Apr 2020	157	0	19
May 2020	150	0	18
Jun 2020	204	0	16
Jul 2020	165	0	29
Aug 2020	76	0	16
Sep 2020	289	0	15
Oct 2020	116	0	12
Nov 2020	175	0	13
Dec 2020	91	0	8
Jan 2021	133	0	14
Feb 2021	112	0	7
Mar 2021	84	0	9
Total	3222	0	347